Reports Q1 revenue $1.2M, consensus $1.07M. “The initiation of our first-in-human study of ABS-101 officially marks Absci’s (ABSI) transition to a clinical-stage biotech company, with ABS-201 also accelerating toward entering the clinic early next year,” said Sean McClain, Founder and CEO. “As we continue to execute across our portfolio of wholly owned, partnered, and co-development programs, and with line of sight to additional new partnerships, I am excited for the pivotal updates we expect to share over the rest of this year, and beyond.”
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABSI:
- AbSci Corp options imply 13.4% move in share price post-earnings
- ABSI Earnings this Week: How Will it Perform?
- Absci price target raised to $9 from $5 at KeyBanc
- Strategic Positioning and Operational Resilience Justify Buy Rating for AbSci
- Absci files to sell 5.71M shares of common stock for holders